- $1.31bn
- $1.66bn
- $303.62m
- 81
- 37
- 76
- 70
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 153 | 199 | 268 | 288 | 304 |
Cost of Revenue | |||||
Gross Profit | 105 | 141 | 178 | 182 | 195 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 132 | 154 | 240 | 259 | 288 |
Operating Profit | 20.3 | 45.6 | 27.7 | 28.6 | 15.5 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -17.7 | 10.9 | -4.86 | 5.42 | -18.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -12.6 | 9.15 | -10 | 1.29 | -42.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -12.6 | 9.15 | -10 | 1.29 | -42.5 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -44.1 | -25.3 | -30.9 | 1.29 | -42.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.523 | -0.14 | -0.293 | 0.055 | -0.5 |
Dividends per Share |